The Role of Chemokines in Cervical Cancers
Authors:
- Fabian GarridoFGFabian Garrido
- Carl Mathis WildCWCarl Mathis Wild
- Johanna MittelbergerJMJohanna Mittelberger
- Franziska DoblerFDFranziska Dobler
- Mariella SchneiderMSMariella Schneider
- Nadine AnsorgeNANadine Ansorge
- Melitta KöpkeMKMelitta Köpke
- Annamarie StriederASAnnamarie Strieder
- Nina DitschNDNina Ditsch
- Udo JeschkeUdo Jeschke
- Christian DanneckerCDChristian Dannecker
Open Access
Abstract
Both clinical-pathological and experimental studies have shown that chemokines play a key role in activating the immune checkpoint modulator in cervical cancer progression and are associated with prognosis in tumor cell proliferation, invasion, angiogenesis, chemoresistance, and immunosuppression. Therefore, a clear understanding of chemokines and immune checkpoint modulators is essential for the treatment of this disease. This review discusses the origins and categories of chemokines and the mechanisms that are responsible for activating immune checkpoints in cervical dysplasia and cancer, chemokines as biomarkers, and therapy development that targets immune checkpoints in cervical cancer research.Keywords
This publication has 85 references indexed in Scilit:
- CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patientsBritish Journal of Cancer, 2012
- CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistributionOncology Letters, 2011
- Identification of the Chemokine CX3CL1 as a New Regulator of Malignant Cell Proliferation in Epithelial Ovarian CancerPLOS ONE, 2011
- Human Papillomavirus Testing in the Prevention of Cervical CancerJNCI: Journal of the National Cancer Institute, 2011
- Correlation of CXCL12 Expression and FoxP3+ Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical CancerThe American Journal of Pathology, 2009
- Novel Anti-Metastatic Action of Cidofovir Mediated by Inhibition of E6/E7, CXCR4 and Rho/ROCK Signaling in HPV+ Tumor CellsPLOS ONE, 2009
- Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancerInternational Journal of Cancer, 2007
- Expression of IP-10 related to angiogenesis in uterine cervical cancersBritish Journal of Cancer, 2007
- Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancerAnnals of Oncology, 2006
- Selective suppression of monocyte chemoattractant protein‐1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cellsInternational Journal of Cancer, 2003